The global influenza drug market is experiencing significant growth, driven by the rising incidence of seasonal flu outbreaks and the increasing awareness of the importance of timely treatments. With advancements in antiviral drugs, such as oseltamivir and baloxavir marboxil, the market is seeing an expanding range of treatment options. Additionally, the ongoing focus on improving vaccine coverage and enhancing immune system responses to combat influenza strains is propelling market demand. The emergence of new, more effective antiviral agents, along with the rising global prevalence of influenza, especially in high-risk populations such as the elderly and children, is creating growth opportunities. Government initiatives aimed at bolstering influenza drug availability, coupled with the ongoing research into broader-spectrum influenza treatments, are expected to further drive market expansion.
Global Influenza Drug Market is valued at USD 8.73 billion in 2023 in 2022 and is expected to reach USD 14.22 billion by 2031, with a growing CAGR of 6.5% during the forecast period 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/reports/global-influenza-drug-market
Below are the Top Influenza Drug Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
GSK plc.
|
GSK plc. is a global healthcare company focused on pharmaceuticals, vaccines, and consumer healthcare products. In the global influenza drug market, GSK is a leading player with its wide portfolio of flu vaccines and antiviral treatments. The company’s Fluarix and FluLaval vaccines are widely used across the world, providing protection against seasonal influenza. GSK is committed to enhancing public health through innovation, investing heavily in research and development of new antiviral treatments and vaccines, making it a key contributor to the global fight against influenza.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In June 2023, GSK plc. and BELLUS Health Inc. announced today that GSK has finalized the acquisition of BELLUS, a biopharmaceutical company dedicated to improving the lives of patients with refractory chronic cough (RCC). This acquisition will enhance GSK's portfolio by adding BELLUS's expertise in refractory chronic cough (RCC) treatment, strengthening its position in addressing unmet medical needs in this area.
|
|
2.
|
Sanofi
|
Sanofi is a multinational healthcare company, with a focus on vaccines, biologics, and pharmaceutical treatments. In the influenza market, Sanofi is known for its Fluzone vaccine, which is widely distributed in both seasonal and high-dose formulations for the elderly. Sanofi is a leader in developing flu vaccines and plays a significant role in influenza treatment through its antiviral drugs. The company continues to expand its vaccine offerings and improve the efficacy of its antiviral solutions, with ongoing research to address new strains of the flu virus.
|
Influenza
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In June 2023, Sanofi hosted a Vaccines Investor Event focusing on its pipeline, showcasing how its strategy is backed by vaccines R&D. The company aims for sustained growth in the vaccines business through core franchises in influenza, meningitis, and pediatric vaccines, along with a best-in-class RSV franchise to protect infants, toddlers, and older adults. This event will help Sanofi highlight its strategic focus on vaccines R&D and core franchises, showcasing its potential for sustained growth in the vaccines business.
|
|
3.
|
CSL
|
CSL is a global biotechnology company specializing in immunology, hematology, and respiratory diseases. CSL’s flu vaccine business is largely driven by Seqirus, one of the world’s largest flu vaccine companies. Seqirus develops, manufactures, and supplies a range of influenza vaccines for seasonal outbreaks, with a strong presence in both the northern and southern hemispheres. The company continues to expand its market share through innovation in vaccine formulations and distribution partnerships, helping to address the growing global demand for effective influenza prevention and treatment.
|
|
North America, South America, Asia-Pacific, and Europe
|
In November 2022, CSL has announced that its subsidiary, CSL Seqirus, has signed a collaboration and licensing agreement with Arcturus Therapeutics Holdings Inc to utilize their advanced self-amplifying mRNA (sa-mRNA) vaccine platform technology in the later stages of development. This collaboration will enable CSL Seqirus to leverage Arcturus Therapeutics' advanced sa-mRNA vaccine platform technology, potentially enhancing CSL's vaccine development capabilities.
|
|
4.
|
AstraZeneca
|
AstraZeneca is a global biopharmaceutical company with expertise in oncology, cardiovascular, and respiratory diseases. While not a primary player in the influenza vaccine market, AstraZeneca plays a role in the influenza drug market through its antiviral products and contributions to global vaccination campaigns. AstraZeneca’s FluMist vaccine (a nasal spray vaccine) is particularly used in pediatric populations and those who prefer a non-injection option. AstraZeneca is also involved in ongoing research to develop next-generation treatments and vaccines for respiratory diseases, including influenza.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2023, AstraZeneca has announced a partnership and investment deal with Cellectis, a clinical-stage biotech company, to speed up the development of new therapies in areas with significant unmet medical needs such as oncology, immunology, and rare diseases. This collaboration will allow AstraZeneca to utilize Cellectis' gene editing technologies and manufacturing capabilities to create innovative cell and gene therapy products, enhancing AstraZeneca's portfolio in this field.
|
|
5.
|
F. Hoffmann-La Roche Ltd
|
F. Hoffmann-La Roche Ltd (Roche) is a global leader in pharmaceuticals and diagnostics. Roche’s Tamiflu (oseltamivir) is one of the most widely recognized antiviral treatments for influenza. It remains a cornerstone in the management of influenza infections, particularly for high-risk patients. Roche also focuses on diagnostics and research for respiratory infections, contributing to the development of early diagnostic tools and antiviral therapies. The company’s ongoing commitment to advancing flu treatments, combined with its expertise in diagnostics, places it as a key player in combating seasonal influenza and preparing for potential influenza pandemics.
|
Xofluza
Tamiflu (Oseltamivir)
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In December 2021, F. Hoffmann-La Roche Ltd announced that it finished the repurchase of Roche shares that Novartis had held. Roche and Novartis had announced this repurchase. The repurchase will help in the growth of the revenue of F. Hoffmann-La Roche Ltd.
|
Conclusion
The global influenza drug market is poised for continued growth, fueled by the increasing prevalence of seasonal flu, the development of more effective antiviral treatments, and rising awareness about the importance of timely intervention. The expansion of treatment options, coupled with ongoing research into more comprehensive influenza therapies, is set to drive market demand. Additionally, government initiatives and the focus on improving vaccine coverage further support market growth. With a growing emphasis on combating influenza strains and enhancing treatment outcomes, the influenza drug market is well-positioned for a positive trajectory in the coming years.
